Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
Ramachandran, Raja
Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. [electronic resource] - Nephrology (Carlton, Vic.) Dec 2019 - 1241-1247 p. digital
Publication Type: Journal Article; Observational Study
1440-1797
10.1111/nep.13554 doi
Adolescent
Adult
Antigens, CD19--analysis
Calcineurin Inhibitors--administration & dosage
Costs and Cost Analysis
Dose-Response Relationship, Drug
Drug Monitoring--methods
Drug Resistance
Female
Glomerulosclerosis, Focal Segmental--complications
Glucocorticoids--therapeutic use
Humans
Immunologic Factors--administration & dosage
India
Male
Nephrosis, Lipoid--complications
Nephrotic Syndrome--drug therapy
Rituximab--administration & dosage
Treatment Outcome
Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. [electronic resource] - Nephrology (Carlton, Vic.) Dec 2019 - 1241-1247 p. digital
Publication Type: Journal Article; Observational Study
1440-1797
10.1111/nep.13554 doi
Adolescent
Adult
Antigens, CD19--analysis
Calcineurin Inhibitors--administration & dosage
Costs and Cost Analysis
Dose-Response Relationship, Drug
Drug Monitoring--methods
Drug Resistance
Female
Glomerulosclerosis, Focal Segmental--complications
Glucocorticoids--therapeutic use
Humans
Immunologic Factors--administration & dosage
India
Male
Nephrosis, Lipoid--complications
Nephrotic Syndrome--drug therapy
Rituximab--administration & dosage
Treatment Outcome